Cardiac resynchronization therapy: potential for arrhythmic risk modification

Aim. To evaluate the impact of cardiac resynchronization therapy (CRT) on the risk of sustained ventricular tachyarrhythmias (VT) in patients with heart failure (HF) with a implantable cardioverter-defibrillator (ICD) for the primary prevention of sudden cardiac death.

Material and methods. This single-center prospective clinical study included 470 patients (men, 84%) with HF at the age of 57 (51-62) years with a left ventricular ejection fraction (LVEF) of 29 (25-33)%. There were following exclusion criteria: indications for cardiac surgery, known channelopathies, previously registered VT. Depending on intraventricular conduction disorders, dual-chamber ICDs (42%) or CRT-D (58%) were implanted. After ICD implantation, patients were followed up for 24 months to register the end point — a first-time sustained paroxysm of VT detected by the ICD. A positive response to CRT was established in the case of an increase in LVEF by ≥5% of the initial level.

Results. A total of 388 patients underwent full postoperative follow-up. The studied arrhythmic endpoint occurred on average 21 (0,6) months after implantation in 104 patients (27%) with higher frequency in the ICD group. However, the differences in the VT rate in the study groups were statistically unreliable (30% in the ICD group versus 24% in the CRT-D group, p=0,142). It was found that the VT rate was reliably lower in CRT-responders (118 patients, 53%): 15% compared to 32% in the group of inefficient CRT. A 5% increase in the LFEF reduced the probability of VT occurrence by 3 times (odds ratio [OR]=0,34; 95% of CI: 0,13-0,86; p=002). Significant modification of arrhythmic risk was verified by increasing LFEF to 36-40% (OR=0,72; 95% CI: 0,63-0,82; p=0,04).

Conclusion. The results obtained indicate that effective CRT has the potential to modify arrhythmic risk in patients with HF, especially with an increase in LVEF to the level of 36-40%.

1. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599–726. doi:10.1093/eurheartj/ehab368.

2. Yuyun MF, Erqou SA, Peralta AO, et al. Risk of ventricular arrhythmia in cardiac resynchronization therapy responders and super-responders: a systematic review and meta-analysis. EP Eur 2021;23:1262–74. doi:10.1093/europace/euaa414.

3. Tankut S, Goldenberg I, Kutyifa V, et al. Cardiac resynchronization therapy and ventricular tachyarrhythmia burden. Hear Rhythm 2021;18:762–9. doi:10.1016/j.hrthm.2020.12.034.

4. Younis A, Goldberger JJ, Kutyifa V, et al. Predicted benefit of an implantable cardioverter-defibrillator: the MADIT-ICD benefit score. Eur Heart J 2021;42:1676–84. doi:10.1093/eurheartj/ehaa1057.

5. Nesti M, Ricciardi G, Pieragnoli P, et al. Incidence of ventricular arrhythmias after biventricular defibrillator replacement: impact on safety of downgrading from CRT-D to CRT-P. Minerva Cardiol Angiol 2022;70. doi:10.23736/S2724-5683.20.05352-9.

6. Ferri-Certić J, Zavrl-Džananović D, Ležaić L, et al. Impact of left ventricular pacing threshold on ventricular arrhythmia occurrence in cardiac resynchronization therapy. J Cardiol 2019;74:353–9. doi:10.1016/j.jjcc.2019.03.015.

7. Ilov NN, Stompel DR, Palnikova OV, et al. Echocardiography parameter for evaluation of various effects of cardiac resynchronization therapy. Russ. Jour. of Card. and Cardiovasc. Surg. = Kard. i serd.-sosud. khir. 2022;15(1):19–25. (In Russ.) Илов Н.Н., Стомпель Д.Р., Пальникова О.В. и др. Выбор эхокардиографического показателя для оценки разных эффектов сердечной ресинхронизирующей терапии. Кардиология и сердечно-сосудистая хирургия. 2022;15(1):19–25. doi:10.17116/kardio20221501119

8. 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11):4083. (In Russ.)Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11): 4083. doi:10.15829/1560-4071-2020-4083.

9. Schmitt C, Alt E, Plewan A, et al. Initial experience with implantation of internal cardioverter/defibrillators under local anaesthesia by electrophysiologists. Eur Heart J 1996;17:1710–6. doi:10.1093/oxfordjournals.eurheartj.a014755.

10. Daubert J-C, Saxon L, Adamson PB, et al. 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management: A registered branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society; and in col. Europace 2012;14:1236–86. doi:10.1093/europace/eus222.

11. Ilov NN, Surikova ON, Boytsov SA, et al. Possibilities for predicting ventricular tachyarrhythmias in patients with heart failure with reduced ejection fraction based on surface electrocardiography. First results from a single-center prospective study. Russian Journal of Cardiology. 2021;26(12):4661.(In Russ.) Илов Н.Н., Сурикова О.Н., Бойцов С.А., и др. Возможности прогнозирования риска возникновения желудочковых тахиаритмий у больных хронической сердечной недостаточностью со сниженной фракцией выброса левого желудочка на основе анализа поверхностной электрокардиограммы. Первые результаты одноцентрового проспективного исследования. Российский кардиологический журнал. 2021;26(12):4661. doi:10.15829/1560-4071-2021-4661.

12. Linhart M, Doltra A, Acosta J, et al. Ventricular arrhythmia risk is associated with myocardial scar but not with response to cardiac resynchronization therapy. EP Eur 2020;22:1391–400. doi:10.1093/europace/euaa142.

13. Nakamura T, Fukuzawa K, Kiuchi K, et al. Ventricular arrhythmia events in heart failure patients with cardiac resynchronization therapy with or without a defibrillator for primary prevention. J Arrhythmia 2022;38:1056–62. doi:10.1002/joa3.12795.

14. Ruwald MH, Solomon SD, Foster E, et al. Left Ventricular Ejection Fraction Normalization in Cardiac Resynchronization Therapy and Risk of Ventricular Arrhythmias and Clinical Outcomes. Circulation 2014;130:2278–86. doi:10.1161/CIRCULATIONAHA.114.011283.

15. Valbom Mesquita D, Parreira L, Esteves A, et al. Echocardiographic but not clinical response to CRT is an independent predictor of a better survival free from arrhythmic events. EP Eur 2021;23. h doi:10.1093/europace/euab116.467.

16. Gras D, Clémenty N, Ploux S, et al. CRT-D replacement strategy: results of the BioCONTINUE study. J Interv Card Electrophysiol 2022. doi:10.1007/s10840-022-01440-5.

17. Chen X, Ye Y, Wang Z, et al. Cardiac resynchronization therapy via left bundle branch pacing vs. optimized biventricular pacing with adaptive algorithm in heart failure with left bundle branch block: a prospective, multi-centre, observational study. EP Eur 2022;24:807–16. doi:10.1093/europace/euab249.

18. Martens P, Nuyens D, Rivero-Ayerza M, et al. Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction. Clin Res Cardiol 2019;108:1074–82. doi:10.1007/s00392-019-01440-y.